CSCCP Endorses TruScreen Technology

NZX/ASX Announcement 16 May 2023 New China cervical cancer screening guideline announced by CSCCP to include Truscreen's optical electrical technology Highlights o First national medical guideline in the world to recommend TruScreen technology, expected to drive further sales o China Cervical Cancer Screening Management Guideline (Guideline) of Chinese Society for Colposcopy and Cervical Pathology (CSCCP) endorses TruScreen technology as an Artificial Intelligence Screening Method o The Guideline endorses TruScreen technology as a new method for cervical cancer screening in China Truscreen Group Limited (NZX/ASX:TRU) is pleased to advise that the TruScreen technology has been endorsed in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline, one of the most important specialist medical clinical guidelines governing management of cervical cancer. The news was recently released in a media conference at the first event of the annual CSCCP congress in Beijing. CSCCP's decision to include TruScreen technology in its new Guideline emphasises the role of new technology in a booming Chinese healthcare sector. The decision is based on the body of evidence supporting TruScreen clinical use world-wide and after extensive consultations with healthcare practitioners and decision makers. CSCCP is a member of IFCPC (The International Federation of Cervical Pathology and Colposcopy) which is dedicated to reducing the burden of cervical cancer worldwide. The guideline issued by CSCCP is a leading clinical standard for doctors and other healthcare providers as well as government bodies. CEO, Dr Beata Edling commented: "This important decision by the CSCCP paves the way for the case of effective screening technologies, such as TruScreen, in the drive to eradicate cervical cancer. The recent release of the Blue Paper (see NZX/ASX Announcement 8 May 2023) and the CSCCP's national guideline further validate the use of Artificial Intelligence enabled technology for cervical cancer screening." This announcement has been approved by the Board. For more information, visit www.truscreen.com or contact: Dr Beata Edling Chief Executive Officer beataedling@truscreen.com Guy Robertson Chief Financial Officer guyrobertson@truscreen.com Julia Maguire Investor Relations julia@thecapitalnetwork.com.au End CA:00411510 For:TRU Type:GENERAL Time:2023-05-16 09:56:41